Avalo Therapeutics (NASDAQ:AVTX) CFO Sells $111,886.11 in Stock

Key Points

• Chief Financial Officer Christopher Ryan Sullivan sold a total of 32,874 shares of Avalo in April for about $493,266.16 (including 8,457 shares on April 30 for $111,886.11) and now directly owns 423 shares, a 95.24% decrease in his stake.
• All of the transactions were disclosed in an SEC filing and executed under a pre-arranged Rule 10b5-1 trading plan.
• Avalo shares traded around $13.71 (below the 50-day and 200-day moving averages of $15.29 and $16.19), while analysts' consensus price target is much higher at $44.83 and institutional ownership is about 87.06%.

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) CFO Christopher Ryan Sullivan sold 8,457 shares of Avalo Therapeutics stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $13.23, for a total value of $111,886.11. Following the transaction, the chief financial officer directly owned 423 shares in the company, valued at approximately $5,596.29. The trade was a 95.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Ryan Sullivan also recently made the following trade(s):

• On Wednesday, April 29th, Christopher Ryan Sullivan sold 8,458 shares of Avalo Therapeutics stock. The stock was sold at an average price of $13.09, for a total transaction of $110,715.22.
• On Thursday, April 2nd, Christopher Ryan Sullivan sold 7,980 shares of Avalo Therapeutics stock. The stock was sold at an average price of $17.15, for a total transaction of $136,857.00.
• On Wednesday, April 1st, Christopher Ryan Sullivan sold 7,979 shares of Avalo Therapeutics stock. The shares were sold at an average price of $16.77, for a total transaction of $133,807.83.

Avalo Therapeutics Stock Performance

Shares of AVTX traded up $0.31 during mid-day trading on Friday, reaching $13.71. The stock had a trading volume of 720,705 shares, compared to its average volume of 613,175. The business has a fifty day moving average of $15.29 and a 200 day moving average of $16.19. The firm has a market cap of $366.25 million, a price-to-earnings ratio of -2.39 and a beta of 0.93. Avalo Therapeutics, Inc. has a 12 month low of $3.39 and a 12 month high of $20.72.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last announced its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($1.54) by $1.17. The firm had revenue of $0.06 million for the quarter, compared to the consensus estimate of ($0.21) million. On average, research analysts forecast that Avalo Therapeutics, Inc. will post -4.04 EPS for the current fiscal year.

Institutional Trading of Avalo Therapeutics

Large investors have recently made changes to their positions in the business. Caligan Partners LP purchased a new stake in shares of Avalo Therapeutics during the 3rd quarter valued at about $10,592,000. Balyasny Asset Management L.P. purchased a new position in Avalo Therapeutics in the third quarter worth about $10,390,000. Vanguard Group Inc. increased its stake in Avalo Therapeutics by 314.9% during the third quarter. Vanguard Group Inc. now owns 692,637 shares of the company's stock worth $8,803,000 after acquiring an additional 525,696 shares during the last quarter. Millennium Management LLC increased its stake in Avalo Therapeutics by 380.2% during the fourth quarter. Millennium Management LLC now owns 659,979 shares of the company's stock worth $11,985,000 after acquiring an additional 522,548 shares during the last quarter. Finally, Jennison Associates LLC purchased a new stake in Avalo Therapeutics during the fourth quarter valued at approximately $8,637,000. 87.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Avalo Therapeutics in a research report on Wednesday, April 8th. Guggenheim initiated coverage on Avalo Therapeutics in a research report on Monday, February 2nd. They issued a "buy" rating and a $50.00 target price on the stock. BTIG Research reissued a "buy" rating and set a $40.00 price target on shares of Avalo Therapeutics in a research note on Monday, April 13th. Wolfe Research initiated coverage on Avalo Therapeutics in a report on Thursday, April 9th. They set an "outperform" rating and a $48.00 price target for the company. Finally, Wall Street Zen raised Avalo Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Sunday, March 29th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Avalo Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $44.83.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.